高度结质瘤的臭氧疗法:一个概述
Li Yanchu1, Pu Rong2, Cao Rong1
1Head and Neck Oncology Ward, West China Hospital of Sichuan University, Chengdu, China.
Frontiers in oncology
|June 9, 2023
概括
臭氧疗法对高度质瘤具有前景,可能改善氧气条件并增强辐射治疗. 需要进一步的研究来确定这种侵袭性脑瘤的最佳剂量和管理.
科学领域:
- 神经瘤学神经瘤学
- 臭氧治疗研究研究
- 恶性脑瘤 恶性脑瘤
背景情况:
- 高度质瘤 (三级和四级) 是一种具有侵略性的脑瘤,尽管目前的治疗方法,预后不佳.
- 质瘤患者的平均整体存活时间有限 (9-12个月),需要新的治疗策略.
- 臭氧治疗已在各种癌症的临床前和临床研究中证明有效.
研究的目的:
- 探索臭氧疗法作为高度质瘤的可行治疗选择.
- 研究臭氧疗法的潜力,以改善脑瘤中的氧化,并增强辐射疗法.
- 假设与其他瘤类型相比,质瘤中臭氧治疗的增强疗效.
主要方法:
- 对癌症治疗中臭氧治疗现有文献的综述.
- 对质瘤臭氧治疗的临床前数据和临床证据的分析.
- 讨论拟议的作用机制,重点关注大脑细胞中的有氧糖解.
主要成果:
- 目前,关于专门针对质瘤的臭氧治疗的研究有限.
- 臭氧疗法可以改善大脑细胞中的氧气条件,因为它们依赖有氧糖解.
- 对质瘤的最佳臭氧剂量和给药时间需要进一步调查.
结论:
- 臭氧治疗为改善高度质瘤预后提供了一个有希望的途径.
- 进一步的研究对于在质瘤治疗中建立有效的臭氧治疗方案至关重要.
- 了解臭氧在增强放射治疗中的作用,需要进行专门的研究.
相关概念视频
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Oxidative Cleavage of Alkenes: Ozonolysis
10.7K
In ozonolysis, ozone is used to cleave a carbon–carbon double bond to form aldehydes and ketones, or carboxylic acids, depending on the work-up.
Ozone is a symmetrical bent molecule stabilized by a resonance structure.
Ozone is a symmetrical bent molecule stabilized by a resonance structure.
10.7K
Open Angle Glaucoma: Treatment
497
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
497
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Glaucoma: Overview
633
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
633


